Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.99 USD | -1.32% | -3.39% | +22.49% |
May. 17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
May. 13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Financials (USD)
Sales 2024 * | 26.58M | Sales 2025 * | 78.61M | Capitalization | 189M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -4M | EV / Sales 2024 * | 7.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.4 x |
P/E ratio 2024 * |
-5.79
x | P/E ratio 2025 * |
-26.3
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
Latest transcript on Capricor Therapeutics, Inc.
1 day | -1.32% | ||
1 week | -3.39% | ||
Current month | +13.66% | ||
1 month | +18.85% | ||
3 months | +53.20% | ||
6 months | +99.67% | ||
Current year | +22.49% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 5.99 | -1.32% | 233,813 |
24-05-23 | 6.07 | -2.88% | 196,252 |
24-05-22 | 6.25 | -0.64% | 322,059 |
24-05-21 | 6.29 | -0.16% | 289,256 |
24-05-20 | 6.3 | +1.61% | 404,419 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.49% | 191M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- CAPR Stock